(Q45422901)

English

High levels of persistent expression of alpha1-antitrypsin mediated by the nonhuman primate serotype rh.10 adeno-associated virus despite preexisting immunity to common human adeno-associated viruses

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

14 December 2017

High levels of persistent expression of alpha1-antitrypsin mediated by the nonhuman primate serotype rh.10 adeno-associated virus despite preexisting immunity to common human adeno-associated viruses (English)

1 reference

Europe PubMed Central

14 December 2017

9

object named as

James M Wilson

1 reference

Europe PubMed Central

14 December 2017

author name string

Bishnu P De

1

1 reference

Europe PubMed Central

14 December 2017

Adriana Heguy

2

1 reference

Europe PubMed Central

14 December 2017

Neil R Hackett

3

1 reference

Europe PubMed Central

14 December 2017

Barbara Ferris

4

1 reference

Europe PubMed Central

14 December 2017

Philip L Leopold

5

1 reference

Europe PubMed Central

14 December 2017

John Lee

6

1 reference

Europe PubMed Central

14 December 2017

Lorraine Pierre

7

1 reference

Europe PubMed Central

14 December 2017

Guangping Gao

8

1 reference

Europe PubMed Central

14 December 2017

Ronald G Crystal

10

1 reference

Europe PubMed Central

14 December 2017

publication date

2 November 2005

1 reference

Europe PubMed Central

14 December 2017

Molecular Therapy

1 reference

Europe PubMed Central

14 December 2017

13

1 reference

Europe PubMed Central

14 December 2017

1

1 reference

Europe PubMed Central

14 December 2017

67-76

1 reference

Europe PubMed Central

14 December 2017

Molecular basis of alpha-1-antitrypsin deficiency

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.003

7 January 2021

The alpha 1-antitrypsin gene and its mutations. Clinical consequences and strategies for therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.003

7 January 2021

Alpha 1-antitrypsin deficiency, emphysema, and liver disease. Genetic basis and strategies for therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.003

7 January 2021

Human plasma proteinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.003

7 January 2021

Intrapleural administration of a serotype 5 adeno-associated virus coding for alpha1-antitrypsin mediates persistent, high lung and serum levels of alpha1-antitrypsin

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.003

7 January 2021

Immune responses to adenovirus and adeno-associated virus in humans.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.003

7 January 2021

Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV).

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.003

7 January 2021

Hybrid vectors based on adeno-associated virus serotypes 2 and 5 for muscle-directed gene transfer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.003

7 January 2021

Immune responses to gene therapy vectors: influence on vector function and effector mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.003

7 January 2021

"Sero-switch" adenovirus-mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.003

7 January 2021

Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.003

7 January 2021

Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.003

7 January 2021

Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.003

7 January 2021

Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.003

7 January 2021

Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.003

7 January 2021

Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.003

7 January 2021

Sex significantly influences transduction of murine liver by recombinant adeno-associated viral vectors through an androgen-dependent pathway

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.003

7 January 2021

Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.003

7 January 2021

Clades of Adeno-associated viruses are widely disseminated in human tissues.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.003

7 January 2021

Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.003

7 January 2021

CD40 ligand-dependent activation of cytotoxic T lymphocytes by adeno-associated virus vectors in vivo: role of immature dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.003

7 January 2021

Use of a highly purified alpha 1-antitrypsin standard to establish ranges for the common normal and deficient alpha 1-antitrypsin phenotypes

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.003

7 January 2021

AAV2-mediated CLN2 gene transfer to rodent and non-human primate brain results in long-term TPP-I expression compatible with therapy for LINCL.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.003

7 January 2021

Immune responses to adeno-associated virus and its recombinant vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.003

7 January 2021

Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.003

7 January 2021

Gene therapy in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.003

7 January 2021

AAV-mediated gene transfer for hemophilia

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.003

7 January 2021

Safety of adeno-associated virus gene therapy vectors: a current evaluation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.003

7 January 2021

Current status of gene therapy for inherited lung diseases

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.003

7 January 2021

From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.003

7 January 2021

Progress in the use of adeno-associated viral vectors for gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.003

7 January 2021

Adeno-associated virus and the development of adeno-associated virus vectors: a historical perspective

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.003

7 January 2021

Integration of adeno-associated virus (AAV) and recombinant AAV vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.003

7 January 2021

Stable therapeutic serum levels of human alpha-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV) vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.003

7 January 2021

Intramuscular administration of recombinant adeno-associated virus 2 alpha-1 antitrypsin (rAAV-SERPINA1) vectors in a nonhuman primate model: safety and immunologic aspects

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.003

7 January 2021

Phase I trial of intramuscular injection of a recombinant adeno-associated virus alpha 1-antitrypsin (rAAV2-CB-hAAT) gene vector to AAT-deficient adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.003

7 January 2021

Strategies for aerosol therapy of alpha 1-antitrypsin deficiency by the aerosol route

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.003

7 January 2021

Clinical gene transfer studies for hemophilia B.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.003

7 January 2021

Route of administration determines induction of T-cell-independent humoral responses to adeno-associated virus vectors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.003

7 January 2021

Transduction by adeno-associated virus vectors in the rabbit airway: efficiency, persistence, and readministration.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.003

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.YMTHE.2005.09.003

1 reference

Europe PubMed Central

14 December 2017

1 reference

Europe PubMed Central

14 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45422901&oldid=2076922146"